All good Sir! I spotted you living the dream on some other minnows since the new year :)As I've said previously, you are very good at this game!Looking forward to this going Northwards. |
Hiya beeks
Very well thanks and yourself ? |
Morning Z1co. Hope you are well. |
 January 27, 2025
First neonatal baby avoids lifelong hearing loss thanks to ground-breaking gene test
A baby receiving care in Bolton’s Neonatal Unit has benefitted from a ground-breaking test
Genedrive rapidly tests whether babies could go deaf after being given certain antibiotics
November 2024 saw the first positive test come back allow for a change in prescription
A baby receiving care in Royal Bolton Hospital’s Neonatal Unit has become the first to benefit from a ground-breaking gene test which aims to prevent lifelong hearing loss.
Royal Bolton was one of the first hospitals to go live with the cutting edge Genedrive System, which uses a cheek swab to rapidly detect potential genetic mutations which can cause permanent hearing loss in babies when they are given aminoglycoside antibiotics.
The system means babies admitted to the Neonatal Intensive Care Unit with sepsis are rapidly tested and given an alternative antibiotic if they are positive, avoiding a lifetime of deafness.
In November 2024, the programme saw its first instance where a positive test came back, allowing for a change of planned prescribed antibiotics.
Jamie Osborne, Principal Biochemist and Point of Care Testing Clinical Lead at Bolton NHS Foundation Trust, said:
Advancements in technology are enabling us to drastically transform the care we’re able to provide to some of our most vulnerable patients.
“These interventions are already helping our babies avoid lifelong hearing loss, transforming the lives of patients and their families.
“We’re incredibly proud of the technology and that Bolton is amongst the first sites in the world to adopt it. The work we’re doing here will be critical to ongoing technology assessments by the National Institute for Health and Care Excellence.
The Genedrive System, funded as a pilot study by Health Innovation Manchester, was developed in partnership with Manchester University NHS Foundation Trust. |
What a success we will become.
Amazing story |
Hi hazl
Share price has bottomed out at around 2p and will rise strongly ahead of news. |
A decent rns could easily skyrocket the share price by over 100%
The US remains an important target market for our CYP2C19 product, with recent recommendations published by key opinion leaders in the American Heart Association highlighting the need for CYP2C19-genotype guided prescription of Clopidogrel in cardiovascular indications, and we will progress the process for attaining regulatory approval there in the future. |
What a tool Indian idiot
Lots of buys at 2.15p on my L2
2.25p with 3 MMS!! |
Good we are picking up. |
Get out of this share NOW
It's going sub 2p |
Are GDR doing investor roadshows? |
NIHR and OLS Funding Package to address NICE Real World Evidence Generation Requirements for the Genedrive® MT-RNR1 ID Kit"
According to rumours on social media GDR have secured additional £1.25 million of funding that was applied for in November |
Earth shattering placing imminent |
Was NT to buy in excess of 25,000 @ 2.10p and MM's have upped the offer to 2.15p.
Any positive news regarding their tests could see the share price increase significantly higher from the current levels.
Take a look TRLS increased more than 500% , IMM up more than 400% , GENI increased nearly 200% last before profit taking.
News cannot be too far away |
Genedrive continues to roll out the MT-RNR1 Kit across the UK |
genedrive
4,376 followers
2d
👋 Welcome Kimberly Howard, Genedrive’s Product Manager!
Kimberly brings her experience in molecular diagnostics to Genedrive as we continue to roll out the MT-RNR1 ID Kit across the UK. |
Exhibit A. |
Placing will come very soon |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
